Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/38708
Type
ArticleCopyright
Restricted access
Collections
- INI - Artigos de Periódicos [3505]
Metadata
Show full item record
TARGETING ROBO4-DEPENDENT SLIT SIGNALING TO SURVIVE THE CYTOKINE STORM IN SEPSIS AND INFLUENZA
Author
Affilliation
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
Stanford University. School of Medicine. Department of Biochemistry. Stanford, CA, USA / Howard Hughes Medical Institute. Stanford, CA, USA / Stanford University. School of Medicine. Department of Medicine. Division of Cardiovascular Medicine. Stanford, CA, USA.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
Utah State University. Institute for Antiviral Research. Logan, UT, USA.
Utah State University. Institute for Antiviral Research. Logan, UT, USA.
University of Utah. Department of Medicine. Salt Lake City, UT, USA.
Stanford University. School of Medicine. Department of Biochemistry. Stanford, CA, USA / Howard Hughes Medical Institute. Stanford, CA, USA.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
Stanford University. School of Medicine. Department of Biochemistry. Stanford, CA, USA / Howard Hughes Medical Institute. Stanford, CA, USA / Stanford University. School of Medicine. Department of Medicine. Division of Cardiovascular Medicine. Stanford, CA, USA.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
Utah State University. Institute for Antiviral Research. Logan, UT, USA.
Utah State University. Institute for Antiviral Research. Logan, UT, USA.
University of Utah. Department of Medicine. Salt Lake City, UT, USA.
Stanford University. School of Medicine. Department of Biochemistry. Stanford, CA, USA / Howard Hughes Medical Institute. Stanford, CA, USA.
University of Utah. Department of Oncological Sciences. Salt Lake City, UT, USA / University of Utah. Department of Medicine. Salt Lake City, UT, USA / University of Utah. Program in Molecular Medicine. Salt Lake City, UT, USA.
Abstract
The innate immune system provides a first line of defense against invading pathogens by releasing multiple inflammatory cytokines, such as interleukin-1β and tumor necrosis factor–α, which directly combat the infectious agent and recruit additional immune responses. This exuberant cytokine release paradoxically injures the host by triggering leakage from capillaries, tissue edema, organ failure, and shock. Current medical therapies target individual pathogens with antimicrobial agents or directly either blunt or boost the host’s immune system. We explored a third approach: activating with the soluble ligand Slit an endothelium-specific, Robo4-dependent signaling pathway that strengthens the vascular barrier, diminishing deleterious aspects of the host’s response to the pathogen-induced cytokine storm. This approach reduced vascular permeability in the lung and other organs and increased survival in animal models of bacterial endotoxin exposure, polymicrobial sepsis, and H5N1 influenza. Thus, enhancing the resilience of the host vascular system to the host’s innate immune response may provide a therapeutic strategy for treating multiple infectious agents.
Share